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Cancer research has traditionally focused on tumour intra-cellular
gene expression and signalling pathway activation. This view postulates
that cancer cells proliferate due to genetic mutations that activate
growth signalling pathways. While these mechanisms are necessary
and important events in tumour initiation and progression, they do
not account for the complexity of the microenvironment in which the
tumour sits. Tumours are complex systems composed of not only tu-
mour cells, but stroma containing blood and lymph vessels, ﬁbroblasts,
endothelial cells, and immune cells among others [1]. This TME plays an
essential role in the initiation, growth, and metastatic spread of cancer.
Additionally, while genetic mutations initiate tumourigenesis, numer-
ous post-transcriptional and post-translational mechanisms are at play
within tumour cells and other cells within the TME that ultimately con-
tribute to tumour progression. A large proportion of the human genome
is made up of non-coding RNAs, including two of the most well studied
classes of non-coding RNAs; long noncoding RNA (lncRNA) which are
~200 or more nucleotides in length and microRNAs, which are small
(17–27 nucleotide) non-coding RNAs that regulate approximately
30–60% of all protein-coding genes through post-transcriptional
mechanisms [2,3]. MicroRNAs regulate gene expression by binding to
the 3′UTR of target mRNAs, resulting in translation repression or RNAed Bioscience, Lab 140, CRUK
United Kingdom.
aylor).
. on behalf of Research Network of Cdegradation [4]. Approximately 50% ofmicroRNAs are located in regions
of chromosomal abnormalities that are associated with cancer [5],
meaning that in cancer cells with genetic abnormalities signiﬁcant
changes in speciﬁc microRNA clusters are likely. Particular microRNAs
are known to act as both tumour suppressors and oncogenes in the
development of tumours. For example, the miR-17-92 family of
microRNAs is one of the most well characterised oncomiRs and has
been shown to exert anti-apoptotic effects through its ability to down-
regulate Bim and PTEN tumour suppressors [6]. MiR-21 and miR-155
are alsowell characterised oncomiRs that promote both tumour growth
and metastasis by targeting numerous mRNAs. In contrast, miR-15a,
miR-16-1, miR-34a, and the let-7 family of microRNAs have been
shown to suppress tumour growth and metastasis by inducing apopto-
sis, cell cycle arrest and senescence (reviewed in [4]). In addition to their
functional effects on tumour cell signalling pathways, microRNAs have
been shown to exhibit tissue speciﬁc expression patterns [7], suggesting
that they have potential utility as clinical biomarkers [8].
Cell-free microRNAs are found in the circulation and since their
discovery have become promising diagnostic, prognostic, and therapeutic
response biomarkers for cancer. Indeed, circulatingmicroRNAproﬁles can
be used to identify disease types, with elevated circulating microRNAs
being signiﬁcantly associated with disease-associated genetic variants
[9]. These circulatingmicroRNAs have been found to be present in several
different body ﬂuid types [10,11] and are incredibly stable, being able to
withstand room temperature for extended periods of time and numerous
freeze–thaw cycles [11]. The stability of endogenous microRNAs is in
direct contrast to synthetic exogenous microRNAs spike-ins (e.g. cel-
miR-39-3p) which when added to serum or media are rapidly degradedomputational and Structural Biotechnology. This is an open access article under the CC BY
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hypothesised to be protected by being enclosed in extracellular vesicles
or bound to proteins [11–13]. Given their prevalence and stability in
bioﬂuids it is not surprising that recent evidence points to extracellular
microRNAs playing functional roles as autocrine, paracrine, and endocrine
signalling molecules.
Here we review the mechanisms governing cellular release of
microRNAs and the evidence for extracellular microRNA activity in
cell-cell communication with a focus on how cell-free microRNAs
have been shown to have functional roles inﬂuencing tumour progres-
sion and metastasis.
2. Extracellular Vesicles
The term extracellular vesicle encompasses exosomes, microsomes
and apoptotic bodies [14,15]. Exosomes are 30–100 nm in size and are
formed from inward budding of the endosomal membrane [16]. This
forms a multivesicular body (MVB) which contains several exosomes.
The MVB then fuses with the plasma membrane and releases the
exosomes from the cell [17,18]. The resulting vesicles contain cytosol
and can be characterised by the presence of tetraspanin proteins CD9,
CD63, CD81, and CD82 [15]. Other vesicles in the circulation include
microsomes which are produced from the disruption of the plasma
membrane and are of a larger size than exosomes 100–1000 nm and
apoptotic bodies which are released from apoptotic cells and are
1 μm–5 μm in size [19]. Therefore, studies looking at the selective re-
lease ofmicroRNAs have focused on the exosomal fraction of extracellu-
lar vesicles. It must be noted that it is difﬁcult to achieve pure isolates of
exosomes experimentally, meaning that most studies report RNA data
from enriched populations of exosomes which still contain protein
bound microRNAs or other extracellular vesicles [14,15]. Studies have
sought to examine if circulating microRNAs are mainly protein bound
or enclosed in extracellular vesicles. Turnchovich et al. [12] found that
themajority of circulatingmicroRNAs are associatedwith AGO2 protein
and only a small proportion of circulatingmicroRNAs are enclosed in ex-
tracellular vesicles. They hypothesised that microRNA/AGO2 complexes
are released by cells during apoptosis [12]. A global proﬁling study has
suggested that AGO2 may play a role in a selective pathway, which tar-
gets microRNAs into extracellular vesicles [20]. This study compared
different cell lines and identiﬁed a subset ofmicroRNAs that are released
in extracellular vesicles through a common mechanism for sorting
microRNA [20]. These microRNAs are not processed through the canoni-
cal pathway by Dicer, but through an AGO2 mediated maturation
pathway, which leads to preferential release in extracellular vesicles [20].
3. Exosomal RNA Function
Several types of RNA have been found in exosomal fractions, with
microRNAs and mRNAs being the most abundant species. These
microRNAs and mRNAs were found to be enclosed inside exosomes,
as opposed to being attached to the outside. Exosomes isolated from
cultures of glioblastoma cells were found to fuse with the membranes
of host cells and release the contents into the host cell [21]. The
exosomal contents were found to be fully functional in recipient cells,
with microRNAs promoting the downregulation of their targets [21]
and exosomal mRNAs being translated into protein in the host cell [22].
In contrast, a study by Chevillet et al. [23] questions the physiological rel-
evance of exosomal microRNA, as stoichiometric analysis of the absolute
copy number of microRNAs and the number of exosomes indicates that
even for abundant cancer biomarkers (in this case prostate cancer)
there is less than one microRNA copy per exosome. Therefore, this
study brings into question whether or not exosomal microRNAs are in
sufﬁcient abundance in exosomes to have an effect on the recipient
cells. Potentially, a high level of exosome uptake or non-canonical
microRNA activation would be required to elicit exosomal microRNA-
mediated effects [23]. However, given that numerous exosomalmicroRNAs have been shown to have functional effects (discussed
below), more research is needed to ascertain the stoichiometric require-
ments for exosomal microRNA function.
4. Passive Release of microRNAs from Cells
Several studies have found that the bulk of microRNA released in
exosomes reﬂects the cellular microRNA expression proﬁle [24,25],
and themajority of microRNAs (~66%) are released from cells passively
by mass action. miR-16 was identiﬁed as a microRNA that represents
this passive exosomal microRNA release, and the amount of miR-16 in
the cell matches the amount found in exosomes [25]. In agreement
with this idea, Squadrito et al. [26] demonstrated that the microRNA
content of exosomes is determined by the levels of themicroRNA target
mRNA in the cell. For example, if there is an abundance of the mRNA
target of the microRNA, the microRNA is bound and this decreases
the amount of that speciﬁc microRNA in the exosomes. If there is a
high abundance of the microRNA relative to its targets, then an in-
creased level of the microRNA is observed in the exosomes, leading
to the suggestion that the exosome pathway is a mechanism to
maintain microRNA:mRNA homeostasis in the cell [26]. In contrast
to this passive release mechanism, a subset of microRNAs are overrep-
resented in exosomes, meaning that they are enriched in comparison
to levels observed in the cell, indicating a selective release mechanism
[25].
5. Selective Release of microRNAs from Cells
Investigation of the mechanistic requirements governing microRNA
inclusion in to exosomes found that the neutral sphingomyelinase 2
(nSMase2) is required for microRNA exosomal release [27]. The
nSMase2 enzyme catalyses the rate limiting step in ceramide synthesis.
Ceramide is required to promote budding in the endosomal compart-
ment. Therefore, inhibition of nSMAse2 inhibits the formation of
exosomes [27,28]. The active selection of microRNAs for packaging
into exosomes has been suggested to be sequence speciﬁc [29],
with the selection of microRNAs for inclusion into exosomes being
determined through the binding of chaperone proteins. The protein
hnRNPA2B1 has been shown to play a key role in targeting a subset of
microRNAs with a speciﬁc motif into exosomes [30]. In addition, 3′
modiﬁcations ofmicroRNAs have been suggested to determinewhether
a microRNA is retained in the cell or exported in exosomes. Indeed,
non-templated additions of 1,2 or 3 bases of uridine or adenosine to
the 3′ end of certain microRNAs has been found to inﬂuence microRNA
release into exosomes, with poly-adenylated microRNAs being more
likely to be retained in the cell and poly-uridynilated microRNAs pack-
aged into exosomes [31].
Alterations in cancer-associated cell signalling pathways also alter
the microRNA proﬁle of exosomes [32,33]. For instance, p53 has been
shown to govern the release of exosomes from cells. On activation by
DNA damage, p53 transcriptionally up-regulates the expression of tu-
mour suppressor activated pathway 6 (TSAP6), which has been found
to be essential for p53-mediated exosome release [34]. Although a
direct mechanism linking changes in microRNA content in these
exosomes has not yet been described, it illustrates the inﬂuence
that cell signalling pathways have on exosomal release. In colorec-
tal cancer cells, exosomal loading has been shown to be dependent
on KRAS mutational status, with mutant KRAS cells releasing
higher levels of miR-100 and wild-type KRAS cells releasing higher
levels of miR-10 into the exosomal fractions [26,35], through a
mechanism requiring nSMAse. Additionally, KRAS-dependent
activation of MEK-ERK signalling inhibits sorting of AGO2 bound
microRNAs into exosomes [36]. Although it is clear that oncogenic
signalling pathways inﬂuence microRNA content in exosomes, the
exact mechanisms by which these microRNAs are sorted into
exosomes and the contribution of passive versus active sorting
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research to determine the contribution of passive and selective
release of microRNAs from cancer cells.
6. Extracellular microRNAs in the Tumour Microenvironment
MicroRNAs expressedwithin tumour cells,ﬁbroblasts, immune cells,
and endothelial cells present in the TME are known to promote tumour
growth and metastasis by targeting mRNAs in their cell of origin, lead-
ing to changes in cellular phenotype and changes in cytokine expression
and secretion [4,37]. Emerging evidence indicates that in addition to
this canonical intracellular mechanism, cell secreted microRNAs can
be delivered to other cells in the tumour microenvironment leading to
reprogramming of the target cell transcriptome and altering tumour
growth, angiogenesis, metastasis and immune function in a paracrine
manner (Fig. 1, Table 1).
6.1. Exosomal microRNA in Cell Fate Determination and Angiogenesis
Stem-cells are hypothesised to inﬂuence the cellular differentiation
of other cells through secretion of growth factors, cytokines, and
exosomes. Indeed, mesenchymal stem cell (MSC) - derived exosomes
isolated from mice with pulmonary hypertension have been shown to
induce pulmonary hypertension in healthy mice [38]. However, the
exact mechanisms through which stem-cell derived exosomes exert
these effects remains unknown. MSCs are recruited to the TME where
they can differentiate into tumour-associated ﬁbroblasts and produce
ECM matrix proteins necessary for the development of a tumour pro-
moting microenvironment [39]. Crosstalk between MSCs and tumour
cells that occurs through the release of exosomal microRNAs has been
shown to have a key role in either suppressing or driving angiogenesis
in tumours. For example, exosomal miR-16 released by MSCs can
suppress angiogenesis by down-regulating VEGF expression in breast
cancer cells [40]. The miR-17-92 cluster contains some of the most
well characterised oncogenic microRNAs and is known to target cell
cycle inhibitors CDKN1A and CDKN1C and E2Fs [41–43]. Signiﬁcant forFig. 1. Cell-free microRNAs are taken up by cells in the tumour microenvironment. MicroRNAs
microRNAs are then taken upby recipient tumour, immune, or stromal recipient cells present in
changes in cell proliferation, differentiation, migration, immune response, and angiogenesis thtumourigenesis, the miR-17-92 cluster promotes angiogenesis by
targeting the anti-angiogenic factors connective tissue growth factor,
thrombospondin-1, and integrin alpha5 [44,45]. In addition to this in-
tracellular signallingmechanism, members of this cluster of microRNAs
have been found to be exported from cells in exosomes [46], with more
recent evidence indicating that these exosomal miRs originating from
tumour cells can elicit changes in the surrounding TME. Interestingly,
miR-92a has been shown to have both pro-angiogenic and anti-
angiogenic roles depending on which cell type it is secreted from.
When released in tumour exosomes it plays a pro-angiogenic role,
whereas when released by MSCs it exhibits an anti-angiogenic role
[46,47]. Exosomal microRNAs released from tumour cells have also
been shown to inﬂuence angiogenesis by effecting MSCs and other
cells in the TME. Exosomal microRNAs released by chronic lymphocytic
leukaemia cells are taken up by both endothelial and mesenchymal
stem cells, altering the transcriptome of stromal cells and leading to
the release of pro-angiogenic factors [48]. Additionally, transformed
lung cancer cells have been shown to transfer miR-21 via exosomes to
nearby normal bronchial epithelial (HBE) cells. This increases VEGF
production and promotes angiogenesis through a STAT3 dependent
mechanism [49]. Similarly, hypoxic conditions induce A549 lung cancer
cells to release miR-494 containing exosomes to surrounding endothe-
lial cells,which leads to the suppression of PTEN andAkt/eNOS pathway
activation, enhancing angiogenesis. Treatment of these tumours with
anti-miR-494 has been shown to inhibit angiogenesis and attenuate
the growth of tumour xenografts in this model [50].
6.2. Exosomal microRNA in the Promotion of Tumour Cell Migration and
Metastasis
The complex process of metastasis involves multiple steps including
local invasion, intravasation, and survival in the vascular system, extrav-
asation, and colonisation of distant organ sites. These steps are often
highly dependent on interactions between the tumour cell and the
local microenvironment [51]. A key step in this process is for cancer
cells to acquire a certain degree of plasticity to adapt to their neware secreted by donor cells through active or passive release mechanisms. These cell-free
the TME,where they elicit functional effects on gene expression in recipient cells leading to
at collectively inﬂuence tumour progression and metastasis.
Table 1
MicroRNA Cell type released
by
Cell type taken up by Extracellular Role Ref.
Angiogenesis
miR-16 MSCs Tumour cells Suppression of angiogenesis by downregulating VEGF. [40]
miR-92a Tumour cells
MSCs
MSC
Endothelial cells
Pro-angiogenic role
Anti-angiogenic role.
[46,47]
miR-21 Tumour cells Bronchial epithelial cells Increase in VEGF production and promotion of angiogenesis [49]
miR-494 Tumour cells Endothelial cells Suppression of PTEN and Akt/eNos pathway activation,
enhancing angiogenesis.
[50]
Migration and metastasis
miR-200 Metastatic tumour cells Non-metastatic tumour cells Promoting mesenchymal-to-epithelial transition and
colonisation of metastatic sites.
[52]
miR-10b Metastatic tumour cells Non-malignant cells Induction of invasive properties [53]
miR-21 Tumour cells Tumour cells Promoting migration and invasion by targeting PDCD4 for
downregulation.
[54]
miR-105 Metastatic tumour cells Endothelial cells Promoting vascular permeability by downregulating ZO-1. [55]
Modulation of tumour-immune response
miR-9 Tumour cells Tumour cells Inhibits expression of MHC class I, preventing recognition of
tumour cells by the immune system.
[57]
miR-21 Tumour cells Macrophages
Myoblasts
Binds to TLRs, inducing the secretion of inﬂammatory cytokines.
Induction of cell-death through activation of the JNK pathway.
[58,60]
miR-223 Macrophages Tumour cells Promotion of tumour cell invasion. [59]
miR-203 Tumour cells Dendritic cells Downregulation of TLR4 expression and decreased production
of cytokines TNF-α and IL-12.
[61]
miR-23 Tumour cells NK cells Downregulation of CD107a leading to immunosuppression. [62]
miR-24-3p, miR-891a, miR-106a-5p,
miR-20a-5p, miR-1908
Tumour cells T-cells Promotes Treg differentiation leading to suppression of
anti-tumour immunity.
[63]
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200c, -141 and -429, was traditionally thought to encode tumour sup-
pressor microRNAs, due to its ability to downregulate Zeb1 expression
and suppress epithelial to mesenchymal transition (EMT). However,
Le M.T. N et al. recently showed that metastatic capability could be
transferred betweenmetastatic and non-metastatic cells via extracellu-
lar vesicles containing miR-200. MiR-200 containing extracellular vesi-
cles taken from metastatic breast cancer cells could confer the ability
to colonise distant tissues onweaklymetastatic breast cancer cells by al-
tering gene expression proﬁles and promoting mesenchymal-to-
epithelial transition [52]. A similar phenomenon has been observed in
metastatic breast cancer cellswhere the secretion ofmiR-10b frommet-
astatic breast cancer cells has been shown to induce invasive properties
on non-malignant cells [53]. Additionally, miR-21 containing exosomes
have been shown to promote migration and invasion of recipient
esophageal cancer cells by targeting programmed cell death 4
(PDCD4) and activating the c-Jun N-terminal kinase (JNK) pathway
[54]. These studies highlight the role that extracellular microRNAs
play in tumour cell-cell communications and mediating plasticity
changes within tumour cells to promote a metastatic phenotype. In ad-
dition to modulating nearby tumour cells, secreted microRNAs can also
act on other cells in the TME to enhance metastasis. For example,
miR-105 is secreted bymetastatic breast cancer cells promotes vascular
permeability by downregulating the tight junction protein ZO-1 in
endothelial cells. Inhibition of miR-105 in highly metastatic tumours
led to a reduction in tumour invasiveness and a restoration of vascular
barrier function, thereby decreasing metastasis [55]. Taken together,
these studies illustrate that exosomal microRNAs secreted by tumour
cells are capable of promoting metastasis by inducing invasive proper-
ties in nearby tumour cells and bymanipulating the tumourmicroenvi-
ronment to enhance tumour cell migration.
6.3. Exosomal microRNA and Modulation of Tumour Immune Response
Tumour progression is intricately linked to the immune response.
Activation of speciﬁc immune cells such as dendritic cells (DCs), naturalkiller cells (NK cells), and CD8+ effector T cells drive potent anti-
tumour responses, while suppression of these cell types promotes tu-
mour survival. Cancers are known to subvert the functions of other
cells in the tumourmicroenvironment, limiting local immune responses
and ultimately leading to enhanced invasion and tumour progression
[56]. Secretion of exosomal microRNAs from various cell types present
in the tumour microenvironment may play a role in modulation of im-
mune response in the tumour microenvironment. Indeed, exosomal
miR-9 secreted by tumour cells has been shown to inhibit expression
of major histocompatibility complex (MHC) class I, thereby preventing
recognition of tumour cells by the immune system [57]. Macrophages
are key regulators of host immunity, and tumour-associated macro-
phages (TAMs) exert immunosuppressive effects through the secretion
of cytokines that suppress anti-tumour responses. It has been demon-
strated by Fabbri M. et al. [58] that exosome-derived microRNAs bind
to human Toll-like receptor 8 (TLR8), which shares the same function
asmurine TLR7. Exosome-derivedmicroRNA binding to these receptors
stimulates downstream NFκB pathway activation and the secretion of
inﬂammatory cytokines in macrophages [58]. Along these same lines,
binding of exosome-derived miR-21 to TLRs on macrophages has been
shown to induce the secretion of inﬂammatory cytokines and the pro-
motion of metastasis [58]. Additionally, IL-4 activated macrophages
have been found to secrete exosomes containing miR-223, which pro-
motes invasion of breast cancer cells [59]. Interestingly, the same secret-
ed microRNA can have differential effects on the microenvironment
depending on what cell type it acts on. For example, when exosomal
miR-21 binds to TLR7/8 on macrophages, it promotes secretion of IL-6,
leading to a pro-inﬂammatory response. However, when miR-21
binds to TLR7 receptors on myoblasts, it promotes cell-death through
activation of the JNK pathway [60]. DCs are antigen presenting cells
(APCs) that play an important role in antitumor response by facilitating
the activation of T-cells in the tumour microenvironment. Pancreatic
cancer cells have been shown to repress DC activation by releasing
exosomes containing miR-203 which is then taken up by DCs resulting
in downregulation of TLR4 expression and decreased production of cyto-
kines TNF-α and IL-12 [61]. Additionally, miR-23 containing exosomes
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the suppression of CD107a and leading to immunosuppression [62].
Exosomally-derived microRNAs have also been shown to modulate
T-cells present in the tumour microenvironment. For instance, exosomal
microRNAs (miR-24-3p, miR-891a, miR-106a-5p, miR-20a-5p, and
miR-1908) secreted by nasopharyngeal carcinoma (NPC) cells have
been shown to promote regulatory T-cell (Treg) generation leading to
suppression of anti-tumour immunity [63]. Tregs themselves have also
been shown to exert some of their immune suppressive effects through
exosomal microRNA-mediated effects. Indeed, microRNAs released in
Treg derived exosomes were shown to inhibit Ptgs2, thereby limiting
Th1 responses [64]. It is clear thatmicroRNAs can impact gene expression
in immune cells. However, the implications of the bi-directional exchange
of microRNA between tumour and immune cells is only beginning to be
uncovered. Given that microRNAs are only one component of the cargo
contained within exosomes, it will be important to gain a better under-
standing of what extent they contribute to exosome-induced changes in
the TME. Moreover, more research is needed to characterise the
microRNAs expressed and secreted from each of the different immune
cell types and to what extent this effects tumour progression.
7. Conclusions and Future Prospects
It is well established thatmicroRNAs play essential roles inmodulat-
ing the intracellular signalling pathways in tumour cells and other cells
present in the TME. Now, emerging data indicates that these processes
are evenmore complex, with the bi-directional exchange of microRNAs
occurring between various cell types present in the TME. The process
ofmicroRNA release occurs both passively and actively, although clearly
more research to deﬁne the exact mechanisms through which
microRNAs are sorted for extracellular release is needed. Further inves-
tigation and understanding ofmicroRNA releasemechanisms, aswell as
the stoichiometry required for functional effects are needed to gain a
better understanding of the mechanisms governing downstream
effects. Moreover, very little is known about the mechanistic require-
ments for microRNA uptake by target cells. Broader understanding of
these processes would greatly contribute to understanding the
complexity of the TME that drives tumour progression and could open
new opportunities for therapeutic intervention or new biomarkers for
the treatment of cancer.
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